FOR IMMEDIATE RELEASE

Clearbridge Health Commencement of Adult Immune Cell Banking Business

- **Adult immune cell banking business targets Southeast Asia and Hong Kong with first commercial patients expected shortly**
- **Asset-light model through exclusive partnership with AABB-accredited biobank enables rapid market entry**
- **Positioned to address growing demand for autologous immune cell storage driven by emerging immunotherapy and cellular therapies**

SINGAPORE, November 3, 2025 – SGX Catalist-listed Clearbridge Health Limited (1H3) ("**Clearbridge Health**", the "**Company**", and together with its subsidiaries, the "**Group**"), a healthcare company with a focus on the delivery of precision medicine, is pleased to announce the launch of its adult immune cell banking business, targeting Southeast Asia and Hong Kong as its primary markets. The business is operated through the Company's wholly-owned subsidiary, Cell Entrust Bio Co. Limited ("**CEB**"), based in Hong Kong and leverages its business presence and networks in other parts of Southeast Asia.

The cell banking service enables individuals to collect and store their own peripheral blood mononuclear cells ("**PBMCs**") – ready for potential future therapeutic uses. These stored cells are essential for autologous immunotherapy treatments, including CAR-T (Chimeric Antigen Receptor T-cell) therapy, as well as other emerging approved cellular therapies and clinical trials for cancer and other conditions.

CEB, incorporated on 9 July 2025, represents Hong Kong's first biobank focused exclusively on adult immune cell banking. The business has been actively recruiting commercial clients following the completion of trial runs.

Strategic Rationale

The establishment of adult immune cell banking addresses a fundamental requirement in the evolving landscape of precision medicine. As cellular therapies continue to advance globally, there is growing recognition of the importance of banking immune cells whilst individuals are healthy, ensuring optimal cell viability for future therapeutic applications.

This initiative serves multiple strategic purposes – it generates revenue as a standalone business, supports the Group's broader expansion into the oncology market, and provides an autologous source of immune cells to meet increasing demand in Asia for other approved and clinical trial cellular therapies.

Asset-Light Model

Clearbridge Health has adopted an asset-light approach by partnering exclusively with a locally licensed and AABB-accredited biobank in Hong Kong, a strategic move to enable immediate revenue generating business and saving lead time than establishing its own greenfield laboratory facility. This exclusivity agreement grants the Group commercial rights to the biobanking services in Hong Kong, Macau, and the broader Greater Bay Area, in addition to Southeast Asia markets.

The AABB accreditation – an internationally recognised standard for blood banking and biotherapies – ensures that the Group's processes align with global quality and safety standards. The biobank's location offers flexibility for clients from Southeast Asia to ship or personally deliver blood samples to Hong Kong.

Bridging the Gap

This new business is positioned to address a market void by offering scalable, consumer-oriented PBMCs banking services that existing providers in Asia do not sufficiently or actively cover. A key differentiator is the emphasis on banking autologous immune cells whilst individuals are healthy, ensuring optimal cell viability for future therapeutic applications – a distinction from fragmented or small-scale competitors in the region.

PBMCs banking can also potentially serve important clinical and research purposes, enabling long-term cryogenic storage of immune cells for use in immunological studies, disease modelling, biomarker discovery, vaccine development, and cell and gene therapy research. The service addresses growing demand driven by emerging cellular therapies, including CAR-T and gamma delta T (γδ T) therapies, which require viable cell accessibility in good health.

The Group's commercial model focuses on direct consumer awareness alongside physician channels, aiming for broader market penetration beyond traditional clinical pathways.

Building Synergies

The commencement of the adult immune cellular banking business complements the Group's recent strategic initiatives and it represents a further step in Clearbridge Health's transformation into a precision medicine company with capabilities spanning laboratory services, medical clinics, healthcare investments, and now, adult immune cell banking.

Mr. Jeremy Yee, Executive Director and CEO of Clearbridge Health, commented: ***"The launch of our adult immune cell banking business represents a significant milestone in Clearbridge Health's strategic evolution. Our asset-light model enables us to serve the substantial and underserved markets of Southeast Asia and Hong Kong, addressing a fundamental need as cellular therapies continue to gain regulatory approvals globally.***

This business is designed to be scalable and revenue-generating from the outset, whilst strengthening our position across the cellular therapy value chain. We are building a company with diversified revenue streams and meaningful exposure to high-growth areas of precision medicine, underpinned by our debt-free balance sheet and disciplined operational approach."

- End -

This press release is to be read in conjunction with the Company's announcement released on 6 June 2025 and the Company's press release on 18 August 2025 which can be downloaded via https://www.sgx.com/securities/company-announcements.

About Clearbridge Health Limited

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. The Group's vision is to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management and tailor personalised prevention and timely treatment programmes for patients. The Group's technology agnostic approach allows it to adopt the most appropriate technology in each segment of its business and the products and/or services it offers. The Group's business comprises (a) provision of laboratory testing services; (b) ownership and operation of medical clinics/centres; and (c) strategic equity participation in precision medical technology companies which complement its business objectives.

For more information, please visit http://www.clearbridgehealth.com

---

*This press release has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").*

This press release has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.